Ronald T. Mitsuyasu

Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients.

D. Golde, G. Baldwin, J. Gasson, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients.

R. Gale, R. Busuttil, R. Champlin, 1988, Reviews of infectious diseases.

Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.

J. V. Von Roenn, E. Cesarman, J. Sparano, 2010, Blood.

Recombinant human granulocyte colony-stimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection.

J. Egrie, J. Glaspy, K. Alton, 1990, Blood.

Characterization of a distinct subgroup of high-risk persons with Kaposi's sarcoma and good prognosis who present with normal T4 cell number and T4:T8 ratio and negative HTLV-III/LAV serologic test results.

J. Fahey, P. Nishanian, R. Mitsuyasu, 1986, The American journal of medicine.

Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine.

G. Baldwin, J. Glaspy, S. Miles, 1991, Blood.

HIV protease inhibitors: immunological insights.

R. Mitsuyasu, Ronald T. Mitsuyasu, 1999, AIDS.